{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Bull Run Capital, Inc. located in Vancouver, BC, Canada.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/11/30/2018-26016.html","cfr_references":[],"citation":"83 FR 61659","comment_url":null,"comments_close_on":"2018-12-17","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 17, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-26016","effective_on":null,"end_page":61659,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/11/30/2018-26016.xml","html_url":"https://www.federalregister.gov/documents/2018/11/30/2018-26016/prospective-grant-of-an-exclusive-patent-license-agonistantagonist-compositions-and-methods-of-use","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-26016?publication_date=2018-11-30","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-11-30/2018-26016/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":146,"last_updated":"2026-04-04 16:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-11-30/pdf/2018-26016.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-26016.pdf?1543499126","publication_date":"2018-11-30","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/11/30/2018-26016.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T07:19:03Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":61659,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use","toc_doc":"Prospective Grant of an Exclusive Patent License","toc_subject":null,"topics":[],"type":"Notice","volume":83}